Studies have shown that 6MP has a short plasma half-life of between 1 and 2 h and is quickly removed via the renal system
Manufacturing is done at an FDA registered facility which complies with NSF and GMP guidelines
13 The very high, sustained, and non-physiological levels of exogenous GLP-1 resulting from the administration of these agents may likely explain both some of the mode of action and the adverse effects of GLP-1 RAs
The main neurocognitive disorders in NDD (AD, PD, etc.), conditions related to alcohol and substance abuse, stroke, traumatic brain injury, and depressive disorders are the closest therapeutic targets
Universal response: 100% of participants on 812 mg achieved at least 5% weight reduction [4]
International Journal of Molecular Sciences (2018) 2